No advantage in DFS or OS was observed by combination of D to E when compared to standard FEC100. The best use of FEC 100 regimen in node positive non metastatic patients.

In HER2-positive patients, OS was improved in the same compared to FEC100, but the same was not observed in DFS.

Between February 2001 and August 2004, 3,010 pts were randomized in France and Belgium. Pts characteristics were well balanced.

A positive interaction test was found and favored ED for the HER2 positive sub group does not confer superior DFS compared to FEC 100.

In women with node positive early stage breast cancer the combination of epirubicin and docetaxel does not confer superior DFS compared to FEC 100.

Radiotherapy was given after conservative surgery. Hormone therapy was prescribed to pts with positive hormone receptors.

In women with node positive early stage breast cancer the combination of epirubicin and docetaxel does not confer superior DFS compared to FEC 100.